Display options
Cite
Rasoul S, Svilaas T, Ottervanger JP, et al. A quantitative analysis of the effect of glucose-insulin-potassium in acute myocardial infarction. Neth Heart J. 2006;14(1):19-23
Rasoul, S., Svilaas, T., Ottervanger, J. P., Timmer, J. R., van 't Hof, A. W., & Zijlstra, F. (2006). A quantitative analysis of the effect of glucose-insulin-potassium in acute myocardial infarction. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, 14(1), 19-23.
Rasoul, S, et al. "A quantitative analysis of the effect of glucose-insulin-potassium in acute myocardial infarction." Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation vol. 14,1 (2006): 19-23.
Rasoul S, Svilaas T, Ottervanger JP, Timmer JR, van 't Hof AW, Zijlstra F. A quantitative analysis of the effect of glucose-insulin-potassium in acute myocardial infarction. Neth Heart J. 2006 Jan;14(1):19-23. PMID: 25696550; PMCID: PMC2557225.
Copy Download .nbib Format: NLM
Share it on

Neth Heart J. 2006 Jan;14(1):19-23.

A quantitative analysis of the effect of glucose-insulin-potassium in acute myocardial infarction.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation

S Rasoul, T Svilaas, J-P Ottervanger, J R Timmer, A W J van 't Hof, F Zijlstra

PMID: 25696550 PMCID: PMC2557225

Abstract

OBJECTIVE: To review the currently available data to investigate the clinical benefit of high- and low-dose glucose-insulin-potassium (GIK) in patients with ST-segment elevation acute myocardial infarction (STEMI).

DESIGN: Quantitative analysis of all randomised trials on GIK in patients with STEMI. Electronic and manual searches for randomised controlled trials of GIK in STEMI were performed with regard to inclusion criteria, dose of GIK and additional use of reperfusion therapy, and a meta-analysis with the primary endpoint 30-day mortality was performed.

PATIENTS: Data from 16 randomised trials, involving 26,273 patients, were included.

RESULTS: Studies were conducted between 1962 and 2005. Overall, hospital mortality was 9.6% after GIK compared with 10.2% in controls (p=0.088). GIK infusion was not associated with an increase in major adverse events.

CONCLUSION: This quantitative analysis of GIK in patients with STEMI did not show a beneficial or detrimental effect of GIK infusion on 30-day mortality. GIK infusion should not be part of the standard therapy for patients with STEMI.

Keywords: GIPS; glucose-insulin-potassium; myocardial infarction; reperfusion

References

  1. Am J Cardiol. 1981 Aug;48(2):361-5 - PubMed
  2. Circulation. 1997 Aug 19;96(4):1152-6 - PubMed
  3. Lancet. 1969 Sep 13;2(7620):559-64 - PubMed
  4. Acta Cardiol. 2000 Feb;55(1):9-15 - PubMed
  5. Br Heart J. 1977 Jul;39(7):748-57 - PubMed
  6. Lancet. 1983 Aug 20;2(8347):419-22 - PubMed
  7. J Am Coll Cardiol. 2003 Sep 3;42(5):784-91 - PubMed
  8. Circ Res. 1991 Feb;68(2):466-81 - PubMed
  9. Am Heart J. 1987 Jul;114(1 Pt 1):54-8 - PubMed
  10. Lancet. 1974 Feb 23;1(7852):284-8 - PubMed
  11. Lancet. 1965 Sep 25;2(7413):607-9 - PubMed
  12. Cardiovasc Res. 2003 Feb;57(2):312-9 - PubMed
  13. Lancet. 1968 May 4;1(7549):946-8 - PubMed
  14. Lancet. 1994 Jan 15;343(8890):155-8 - PubMed
  15. Am J Cardiol. 1962 Feb;9:166-81 - PubMed
  16. Am J Cardiol. 1979 Apr;43(4):801-9 - PubMed
  17. Eur Heart J. 2005 Apr;26(7):650-61 - PubMed
  18. N Engl J Med. 2001 Nov 8;345(19):1359-67 - PubMed
  19. J Am Coll Cardiol. 1995 Jul;26(1):57-65 - PubMed
  20. Circulation. 1998 Nov 24;98(21):2227-34 - PubMed
  21. J Clin Endocrinol Metab. 2000 May;85(5):1868-73 - PubMed
  22. Cardiovasc Drugs Ther. 1999 May;13(3):191-200 - PubMed
  23. Am J Physiol. 1994 Nov;267(5 Pt 2):H1785-94 - PubMed
  24. JAMA. 2005 Jan 26;293(4):437-46 - PubMed
  25. Cardiovasc Res. 1978 Jul;12(7):429-35 - PubMed
  26. Am J Physiol. 1973 Sep;225(3):651-8 - PubMed
  27. Acta Med Scand. 1971 Sep;190(3):213-8 - PubMed

Publication Types